The Battle for Obesity Drugs: Lilly's Expansion in Germany and the Competition with Novo Nordisk

In recent news, Eli Lilly announced its plans to invest $2.5 billion in building a production facility in Germany to meet the growing demand for its diabetes and obesity medications.

The new facility will be located in Alzey, Rhineland-Palatinate, Germany. According to Lilly, the plant will create 1,000 jobs for highly skilled workers such as engineers, operators, and scientists. The company also expects to create 1,900 jobs during the construction phase, which is set to begin in 2024. Additionally, Lilly plans to invest $100 million in Germany's life sciences and biotechnology startup ecosystem.

The strong demand in the diabetes/obesity product market calls for increased production capacity, making the establishment of this new facility a top priority for Lilly.

According to the company's announcement, the facility will be its first large-scale manufacturing base in Germany and will enhance Lilly's production of injectables and equipment manufacturing. When the new site becomes operational in 2027, the addition of the German workforce will play a crucial role in strengthening Lilly's insulin supply.

This announcement comes at a time when the biopharmaceutical industry is striving to meet the growing demand in the obesity treatment market.

On November 8th, Lilly announced the FDA approval of its GLP-1R/GIPR dual-target agonist, tirzepatide, for weight management indications. Tirzepatide is the first drug to be approved that simultaneously activates two intestinal hormone receptors (GIP and GLP-1). The establishment of the new facility is directly related to this medication.

With the approval of weight management indications, the challenge shifts to market supply. Due to its superior glucose-lowering and weight-reducing effects, GLP-1 products have experienced a supply shortage in the past. Therefore, expanding production capacity through the establishment of this facility is crucial for Lilly to meet market demand.

According to the announcement, the German manufacturing site will be Lilly's sixth production base in Europe. The company currently has two production sites in Ireland and one each in France, Italy, and Spain. Lilly stated that its global investment in production facilities has exceeded $11 billion over the past three years.

Lilly vs. Novo Nordisk

The battle of obesity drugs continues

The competition between Lilly and Novo Nordisk in the field of obesity drugs has evolved from indications to production capacity. Both companies have faced challenges of insufficient production capacity due to high market demand.

Currently, tirzepatide has been approved for weight management indications, resulting in a tie in terms of indications. The next determining factor for their dominance in the weight management market is which company can address the production capacity issue most efficiently.

Novo Nordisk has also adopted an expansion strategy to address the issue.

Earlier, Novo Nordisk announced increased investments in expanding or building new facilities in Kalundborg and Bagsværd, Denmark, and Clayton, the United States.

In November last year, Novo Nordisk announced a 5.4 billion Danish Krone (approximately $749 million) investment in expanding its Bagsværd facility in Denmark to enhance the production capacity of its active pharmaceutical ingredients (APIs) for clinical trials.

In June this year, Novo Nordisk announced a 15.9 billion Danish Krone (approximately $2.3 billion) investment in expanding its production facility in Hillerød, Denmark.

On November 10th, Novo Nordisk released a statement outlining plans to invest over 42 billion Danish Krone (approximately $6 billion) in expanding its factory in Kalundborg, Denmark. The expansion, covering an area of approximately 170,000 square meters, aims to increase the production capacity of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist.

It is worth mentioning that in July this year, Catalent, the contract manufacturer of semaglutide, faced quality issues, resulting in insufficient production capacity for semaglutide. As a result, semaglutide remains in high demand and short supply.

In the multi-billion-dollar obesity market, Novo Nordisk and Lilly have virtually formed a duopoly. Analysts predict that the market value could reach $200 billion, with Lilly and Novo Nordisk capturing 80% of the market share.

Last week, AstraZeneca also set its sights on the lucrative obesity market by signing a $2 billion contract with Cyclerion for ECC5004. This early-stage candidate drug is also a GLP-1 receptor agonist but designed for oral administration. It is currently being developed for the treatment of obesity, diabetes, and other cardiovascular metabolic diseases.